Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host

Joel D. Meyers, James C. Wade, Charles D. Mitchell, Rein Saral, Paul S. Lietman, David T. Durack, Myron J. Levin, Anthony C. Segreti, Henry H. Balfour

Research output: Contribution to journalArticlepeer-review

173 Scopus citations

Abstract

Intravenous acyclovir was evaluated in the treatment of 97 immunocompromised patients with mucocutaneous herpes simplex virus infection in a randomized, double-blind, placebo-controlled trial. Acyclovir recipients had significantly shorter periods of virus shedding (p < 0.0002) and lesion pain (p < 0.01), and more rapid lesion scabbing (p < 0.004) and lesion healing (p < 0.04). The most common adverse reaction was a low incidence of peripheral vein irritation; no serious toxicity could be definitely attributed to acyclovir treatment even in these seriously ill patients. Intravenous acyclovir offers both safe and effective treatment for mucocutaneous herpes simplex virus infection in the immunocompromised host.

Original languageEnglish (US)
Pages (from-to)229-235
Number of pages7
JournalThe American journal of medicine
Volume73
Issue number1 PART 1
DOIs
StatePublished - Jul 20 1982
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host'. Together they form a unique fingerprint.

Cite this